all D. Gary Gilliland stories

Researchers exploit genetic ‘co-dependence’ to kill treatment-resistant tumor cells

404132862 — Tue, 20 Oct 2009 15:00:53 -0400

Cancer cells fueled by the mutant KRAS oncogene, which makes them notoriously difficult to treat, can be killed by blocking a more vulnerable genetic partner of KRAS, report scientists at the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT.

GlaxoSmithKline and Harvard Stem Cell Institute announce major collaboration agreement

404132862 — Mon, 21 Jul 2008 15:00:05 -0400

GlaxoSmithKline (GSK) and the Harvard Stem Cell Institute (HSCI) today announced that they have entered into a five-year, $25 million-plus collaborative agreement to build a unique alliance in stem cell science to hasten the development of treatments and cures for a range of diseases.

New findings may increase longevity of stem cells

Wed, 11 Jul 2007 10:52:00 -0400

Identifying the mechanisms that control cell life span is one of the more important questions facing stem cell researchers, indeed, all researchers attempting to understand normal and abnormal cell and organ development. So the recent discovery by a Harvard Stem Cell Institute team that a family of well-known transcription factors plays a major role in regulating the life span and longevity of hematopoietic, or blood, stem cells is of particular note. Transcription factors are proteins that participate in the synthesis of RNA using a DNA template.